Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06409130 · ClinicalTrials.gov registry record · Phase 2

Effects of NNC0194-0499, Cagrilintide, and Semaglutide Alone or in Combinations on Liver Damage and Alcohol Use in People With Alcohol-related Liver Disease

A Phase 2 study of Alcohol-related Liver Disease, sponsored by Novo Nordisk A/S.

Completed
Registry status
Phase 2
Development phase
270
Enrollment target
20
Study locations

NCT06409130: Completed Phase 2 study of Alcohol-related Liver Disease, sponsored by Novo Nordisk A/S.

NCT06409130 is a Phase 2 study of Alcohol-related Liver Disease that has completed, run by Novo Nordisk A/S. The registered enrollment target is 270 participants, above the 202-participant average among 3 other Alcohol-related Liver Disease trials with a reported enrollment target (34% higher). The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06409130, a Phase 2 study of Alcohol-related Liver Disease, has completed, sponsored by Novo Nordisk A/S.

COMPLETED
Registry status
Phase 2
Development phase
270 participants
Enrollment target
20
Study locations

Study Summary

The study will look at the effects of NNC0194-0499, cagrilintide and semaglutide, on liver damage and alcohol use in participants with alcoholic liver disease. Participants will get NNC0194-0499, semaglutide, cagrilintide or ''dummy" medicine in different treatment combinations. Which treatment participants get is decided by chance. The study will last for about 39 weeks.

Primary Outcome

Measured as logarithm score

Conditions Studied

Alcohol-related Liver Disease

Interventions

  • DRUG Semaglutide
  • DRUG NNC0194-0499
  • DRUG NNC0194-0499 placebo
  • DRUG Semaglutide placebo (Group A)
  • DRUG Cagrilintide + semaglutide

Study Locations (20)

Florida

  • Covenant Metabolic Specialists LLC - Fort Myers
  • Miguel Rebollar PA - Hialeah
  • UF Hlth Jacksonville - Jacksonville
  • Univ of Miami/Schiff Ctr - Miami
  • Covenant Metabolic Specialists LLC - University Park

Arizona

  • The Institute for Liver Health - Chandler
  • Arizona Liver Center - Tucson
  • Del Sol Research Management, LLC - Tucson

California

  • OM Research LLC - Lancaster
  • California Liver Research Institute - Pasadena

Pennsylvania

  • University of Pennsylvania Hospital - Philadelphia
  • UPMC_Center for Liver Care - Pittsburgh

Illinois

  • Rush University Med. Cntr - Chicago

Kansas

  • Kansas Medical Clinic, PA - Topeka

Louisiana

  • Louisiana Research Center, LLC - Shreveport

Massachusetts

  • Boston Medical Center_Cary - Boston

Trial Details

FieldValue
Enrollment Target 270 participants
Start Date 2024-05-20
Est. Completion 2026-01-12
Phase Phase 2
Novo Nordisk A/S

431 total trials

What the finished NCT06409130 record still lists

NCT06409130 is an interventional study that assigns participants to a tested intervention. The registered 270 participants enrollment target is mid-sized for trials with a published cap, above the 202-participant average among 3 other Alcohol-related Liver Disease trials with a reported enrollment target (34% higher).

The record links to 1 condition, with Alcohol-related Liver Disease appearing as the primary indexed condition, and to 5 interventions - of which Semaglutide is the first listed.

NCT06409130 names 20 study sites across 12 states, led by Florida, Arizona, California.

Frequently Asked Questions

What is clinical trial NCT06409130 about?

NCT06409130 is a clinical study titled "Effects of NNC0194-0499, Cagrilintide, and Semaglutide Alone or in Combinations on Liver Damage and Alcohol Use in People With Alcohol-related Liver Disease". The study will look at the effects of NNC0194-0499, cagrilintide and semaglutide, on liver damage and alcohol use in participants with alcoholic liver disease. Participants will get NNC0194-0499, semaglutide, cagrilintide or ''dummy" medicine in different treatment combinations. Which treatment part...

What is the current status of trial NCT06409130?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 270 participants. The study started on 2024-05-20. Estimated completion is 2026-01-12.

What conditions does trial NCT06409130 study?

This clinical trial studies the following conditions: Alcohol-related Liver Disease.

What interventions are being tested in trial NCT06409130?

The interventions under investigation include: Semaglutide (DRUG), NNC0194-0499 (DRUG), NNC0194-0499 placebo (DRUG), Semaglutide placebo (Group A) (DRUG), Cagrilintide + semaglutide (DRUG).

Who is sponsoring clinical trial NCT06409130?

This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06409130 being conducted?

This trial has 20 study locations across Arizona, California, Florida, Illinois, Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Alcohol-related Liver Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00801489 · 270 participants · Phase 2

    Fludarabine Phosphate, Cytarabine, Filgrastim-sndz, Gemtuzumab Ozogamicin, and Idarubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

  • NCT04372485 · 270 participants · NA

    Using Mobile Health (mHealth) to Improve STI Treatment Adherence Among Adolescents

  • NCT04528446 · 270 participants

    The Impact of Glomerular Disorders on Bone Quality and Strength

  • NCT05215327 · 270 participants · Phase 2

    High vs. Standard Dose Influenza Vaccine in Lung Allograft Recipients

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT06409130, the US trial registry maintained by the National Library of Medicine. NCT06409130 (mid enrollment · wide site footprint · completed) retrieved and formatted by PlainTrial, see methodology.